These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32781546)

  • 1. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
    Fenwarth L; Fournier E; Cheok M; Boyer T; Gonzales F; Castaigne S; Boissel N; Lambert J; Dombret H; Preudhomme C; Duployez N
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
    Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
    Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
    O'Hear C; Rubnitz JE
    Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Oya S; Ozawa H; Morishige S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Sep; 120(3):297-304. PubMed ID: 38963637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
    Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
    Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
    Thol F; Schlenk RF
    Expert Opin Biol Ther; 2014 Aug; 14(8):1185-95. PubMed ID: 24865510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Chauhan L; Shin M; Wang YC; Loken M; Pollard J; Aplenc R; Hirsch BA; Raimondi S; Ries RE; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S; Lamba JK
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
    Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
    Takeshita A
    Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.